Sihuan Pharmaceutical Holdings Group (HKG:0460) expects to report net profit of at least 210 million yuan for the first half of 2026, up at least 217% from a year earlier.

Revenue is expected to be at least 1.14 billion yuan, roughly unchanged from a year earlier, according to a Tuesday Hong Kong bourse filing.

The company attributed the expected profit growth to steady development of its medical aesthetics business, continued commercialization of its innovative drug portfolio, and a significant increase in its share of profit from an associate.

Shares of the pharmaceutical company rose over 1% in recent trade.